Therefore, herein, we sought to investigate the effect of the SGLT2 inhibitor canagliflozin on serum insulin concentrations and the associations of such changes with HF-related clinical parameters of interest, using data obtained from the randomized CANDLE trial for patients with T2D and HF [22]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.